XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
  Depression
  Neuropsychiatry
  Personality Disorders
  Bulimia
  Anxiety
  Substance Abuse
  Suicide
  CFS
  Psychoses
   Bipolar Disorder
   Schizophrenia
  Child Psychiatry
  Learning-Disabilities
  Psychology
  Forensic Psychiatry
  Mood Disorders
  Sleep Disorders
  Peri-Natal Psychiatry
  Psychotherapy
  Anorexia Nervosa
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Schizophrenia Channel
subscribe to Schizophrenia newsletter

Latest Research : Psychiatry : Psychoses : Schizophrenia

   DISCUSS   |   EMAIL   |   PRINT
Oct-6 protein not a biological marker for schizophrenia
Oct 24, 2005, 14:04, Reviewed by: Dr.

Contrary to their previous results, Ubhi and Price found no difference in Oct-6 protein or mRNA expression between patients and controls.

 
The protein Oct-6 is not a biological marker for schizophrenia. The results of a study published today in the open access journal BMC Psychiatry contradict previous findings and show that Oct-6, a protein involved in neurodevelopment, is normally expressed in the adult brain and cannot be used to identify patients with schizophrenia.

Oct-6 was shown to be expressed in the brain of patients diagnosed with schizophrenia, but not in the brain of healthy individuals, in a study led by Jack Price and published in the July 2002 issue of The American Journal of Psychiatry. Kirenjeet Ubhi and Jack Price, from Kings College London, UK have now replicated Price's original study and extended it. Their findings contradict Price's earlier study.

Events affecting brain development are thought to underlie the occurrence of schizophrenia in later life. Oct-6 plays a crucial role in neurodevelopment, and a genetic variation within the Oct-6 gene has been linked to a subset of patients with schizophrenia and bipolar disorder; therefore, Oct-6 seemed like a good candidate for a biological marker for these disorders.

Ubhi and Price extended Price's original study to include patients with bipolar disorder and major depression it has been suggested that schizophrenia shares a common pathology with these disorders. They analysed post-mortem brain samples from 3 groups of 15 patients. The first group had been diagnosed with schizophrenia, the second group with bipolar disorder and the third group with major depressive disorder. They used 15 brain samples of matched healthy individuals as controls. Oct-6 mRNA and protein expression were determined by in-situ hybridization and immunostaining respectively.

Contrary to their previous results, Ubhi and Price found no difference in Oct-6 protein or mRNA expression between patients and controls.
 

- Expression of POU-Domain Transcription Factor, Oct-6, in Schizophrenia, Bipolar Disorder and Major Depression; Kiren Ubhi and Jack Price; BMC Psychiatry 2005, 5:38 (24 October 2005)
 

www.biomedcentral.com

 
Subscribe to Schizophrenia Newsletter
E-mail Address:

 



Related Schizophrenia News

Study aims to identify schizophrenics at risk for type 2 diabetes
Effects of ketamine mimic only some of the symptoms of schizophrenia
Association between famine and schizophrenia may yield clues about genetic basis
Neuropeptide S (NPS) may help in treating schizophrenia
Neuropeptide S (NPS) may help in treating schizophrenia
NMDA receptor hypofunction demonstrated in schizophrenia
Altered NRG1-erbB4 signaling may contribute to NMDA receptor hypofunction in schizophrenia
Transcription factor Elk-1's role in neurodegeneration and schizophrenia
Schizophrenia limits one's ability to perceive body language
Hospitalized schizophrenics are at a higher risk for developing medical/surgical complications


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us